On Monday, July 12, and August 2, 2021, Bioinnovo organizes the First International Congress of Bovine Viral Diarrhea Virus (BVDV), which will be held virtually. Bioinnovo, a public-private partnership between Vetanco and INTA, is the organizer of the First International Congress of Bovine Viral Diarrhea Virus, to be…
RedBio Argentina awarded the poster of Bioinnovo on the latest field results of the first subunit vaccine against the bovine viral diarrhea virus, Vedevax BLOCK. During the 13th RedBio National Symposium 2021, held on June 8-11, with the title “Biotechnology as a Solution to Past Challenges,” technical posters were exhibited. Bioinnovo’s…
Our specialists participated in the “Conference of Research Workers in Animal Diseases 2020” held virtually last December 5-8. The “Conference of Research Workers in Animal Diseases 2020”, locally known as “CRWAD 2020 Conference” took place last December 5-8 in a virtual modality. Bioinnovo–Vetanco and Vetanco USA specialists…
Using two different platforms, Argentine researchers were able to neutralize the virus. Using “nanobodies” obtained from llamas and with egg immunoglobulins There is no doubt: only science will save the world from the COVID19 pandemic. And it is in this field where our researchers rank…
Bioinnovo, a public-private partnership between INTA and Vetanco S.A., will allocate an important support, granted by the Ministry of Productive Development, to increase the production of Vedevax Block in order to meet local demand and open new international markets. This is the first subunit vaccine…
A multidisciplinary team, where Bioinnovo SA participates, developed IgY avian antibodies that neutralize the COVID-19 virus. The project “Development and production of critical reagents for diagnosis and treatment of COVID-19: Nanoantibodies, IgY polyclonal antibodies, and recombinant proteins” gathers researchers of INTA, CONICET, the National Institute of Infectious Diseases…
Algenex, the Spanish company delivering recombinant technologies, a key factor for the development of Vedevax BLOCK, has opened a new production plant for vaccines in the suburbs of Madrid*. The new facility has the capacity to manufacture up to 3.5 kg of recombinant proteins a…
Specialists of the National Institute of Industrial Technology (INTI) and the national company Ivema Desarrollos designed an essential device for a rapid diagnostic test to substitute imports, reduce costs to the half and meet the local demand that is currently with a shortage of stock. This device…
The Andean Country authorized the commercialization of Vedevax Block, the first recombinant vaccine for the control of the virus. The product developed by Bioinnovo SA, a company created by a partnership between the National Institute of Agricultural Technology (INTA) of Argentina and the company Vetanco…
Bioinnovo, the public-private company (INTA–Vetanco) made its first contribution to the macro collaborative project conducted by a scientific committee that brings together more than twenty male and female researchers from different institutions. Those institutions are the Institute of Science and Technology César Milstein (Conicet –…